MBRX logo

Moleculin Biotech, Inc.

MBRX
Healthcare|Biotechnology|US
$8.70
-0.03 (-0.34%)
DCF Value
$90.32
Tangible Book / Share
$1.55
Cash / Share
$25.57
Next Earnings Report
Nov 12, 2026
EPS est. -$8.87
Financing Filings (last 12 months)
9
Shelf registrations / offering prospectuses — latest Aug 21, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (2)

Dec 2027
Est. completion
P2Glioblastoma, IDH-Wildtype
WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
NCT05879250n=39
Aug 2029
Est. completion
P2P3Acute Myeloid Leukaemia (AML)
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
NCT06788756n=312

Recent Press Releases

Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting
Nov 4, 2026 · GlobeNewsWire
Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027
Oct 30, 2026 · GlobeNewsWire
Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial
Oct 20, 2026 · GlobeNewsWire
Moleculin Announces Reverse Stock Split
Oct 16, 2026 · GlobeNewsWire
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit
Oct 7, 2026 · GlobeNewsWire
Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout
Sep 29, 2026 · GlobeNewsWire
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine
Sep 28, 2026 · GlobeNewsWire
Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR
Sep 25, 2026 · GlobeNewsWire
Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
Sep 23, 2026 · GlobeNewsWire
Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings
Sep 14, 2026 · GlobeNewsWire

SEC Filings (180)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 4, 20268-KMaterial eventDocumentIndex
Oct 30, 20268-KMaterial eventDocumentIndex
Oct 20, 20268-KMaterial eventDocumentIndex
Oct 16, 20268-KMaterial eventDocumentIndex
Oct 15, 2026S-8Employee stock planDocumentIndex
Oct 9, 20268-KMaterial eventDocumentIndex
Oct 5, 20268-KMaterial eventDocumentIndex
Sep 29, 20268-KMaterial eventDocumentIndex
Sep 28, 20268-KMaterial eventDocumentIndex
Sep 25, 20268-KMaterial eventDocumentIndex
Sep 23, 20268-KMaterial eventDocumentIndex
Sep 18, 20268-KMaterial eventDocumentIndex
Sep 14, 20268-KMaterial eventDocumentIndex
Aug 31, 20268-KMaterial eventDocumentIndex
Aug 25, 2026SC 13DActivist / 5%+ stakeDocumentIndex
Aug 25, 2026SC 13DActivist / 5%+ stakeDocumentIndex
Aug 24, 2026DEFA14AProxy / shareholder voteDocumentIndex
Aug 24, 2026DEF 14AProxy / shareholder voteDocumentIndex
Aug 21, 2026424B5Offering prospectusDocumentIndex
Aug 14, 2026PRE 14AProxy / shareholder voteDocumentIndex
Aug 14, 20268-KMaterial eventDocumentIndex
Aug 13, 202610-QQuarterly reportDocumentIndex
Aug 10, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 6, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 3, 20268-KMaterial eventDocumentIndex
Aug 3, 2026424B5Offering prospectusDocumentIndex
Jul 31, 2026EFFECTDocumentIndex
Jul 31, 20268-KMaterial eventDocumentIndex
Jul 31, 2026S-1/AIPO / offering registrationDocumentIndex
Jul 30, 2026S-1/AIPO / offering registrationDocumentIndex
Jul 29, 2026S-1IPO / offering registrationDocumentIndex
Jul 15, 2026DRSDocumentIndex
Jun 30, 20268-KMaterial eventDocumentIndex
Jun 30, 20268-KMaterial eventDocumentIndex
Jun 5, 20268-KMaterial eventDocumentIndex
May 29, 20268-KMaterial eventDocumentIndex
May 26, 20268-KMaterial eventDocumentIndex
May 22, 20268-KMaterial eventDocumentIndex
May 15, 20268-KMaterial eventDocumentIndex
May 14, 202610-QQuarterly reportDocumentIndex